Value Microcaps Zip Code Changers

[Potse]

ECGI(.07)...BreastCare DTS business plan update.....

I continue to hold my position in ECGI, and still expect to see prices well above the 20-cent level at some point. IMO, the 5-10 cent area looks reasonably attractive for entry/accumulation of both core and trading positions. If the company successfully executes on its current business plan, I am anticipating significant tradeable opportunities in the ECGI stock over the next 12+ months.

This week the company started putting updated business/financial presentations on the investors section of its website. It appears much of the final packaging design for the NowCardio system/product has been completed. The target time frame for the ramp-up of the BreastCare DTS business/product appears to be the first quarter of 2016. The anticipated blanket purchase orders mentioned in the business plan would represent annual revenues exceeding $20M.

Some items of interest from the May 2015 BreastCare DTS business plan.....

1)

ECGI currently intends to launch the BreastCare DTS™ device in the Australia and China through its network of distribution partners.

2)

ECGI has retained Ceres Technologies to engineer and design of the BreastCare DTS? production line. ECGI anticipates contract manufacturing the BreastCare DTS? device with Ceres Technologies. Ceres Technologies is an industry leader in electronics grade ultra high-purity and precision delivery systems for gases and precursors. The Company will also manufacture at other locations around the world as demand for BreastCare DTS™ increases.

The intellectual property underlying the production process may provide additional protection from future potential competitors. Ceres has completed the design of the Company’s manufacturing line and performed a bench test to show that the proprietary dispensing system functions successfully according to specifications and needs only to be scaled to full production. The Company will employ sustainable manufacturing practices to minimize waste and energy utilization during processes, packaging and shipping.

3)

The Company currently anticipates that the first new manufacturing line will begin production in the first quarter of 2016.

4)

ECGI has been actively engaged in obtaining purchase commitments outside the U.S., for the bulk of the first year’s anticipated production. Currently, the Company:
?
Has signed a licensing agreement with MedPac Asia Pacific PTY Ltd, of Australia, granted the exclusive distribution rights for the BreastCare DTS™ device in Australia, New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Laos, Cambodia, Myanmar and Bangladesh. It is anticipated that the distribution agreement will become a blanket purchase order for 25,000 units per month for year one of production and to increase as demand and production capability for the BreastCare DTS™ device increases.
?
Is in the final stages of signing a licensing agreement with a Chinese company for China, Hong Kong, Japan, Korea and Taiwan. It is anticipated that the distribution agreement will become a blanket purchase order for 75,000 units per month for year one of production and to increase as demand and production capability for the BreastCare DTS™ device increases.
?
Is also involved in discussions with potential distributors in a number of other countries.

http://www.eventcardiogroup.com/wp-content/uploads/2015/06/1-Business-Plan-Breast-Care-May-2015.pdf